Treatment Regimens
The majority of patients (n=136, 85.5%) received systemic medical therapy (Table 2) and systemic therapy was more common in patients with KMP versus those without KMP (95.3% vs. 70%, p=0.05). Siro was the most common treatment (n=51, 32.1%), followed by steroids (n=32, 20.1%), beta-blocker or minimal/none (n=27, 17%), VCR (n=25, 15.7%), surgical/interventional radiology (IR) (n=17, 10.7%), and Siro+VCR (n=7, 4.4%). Time from initial symptoms to treatment initiation (16 vs 169 days, p<0.001) and time from diagnosis to treatment initiation (3 vs. 21 days, p <0.001) were both shorter for patients with KMP compared to those without KMP. Patients with KMP received more blood product transfusions (78.1% vs 6.3%, p<0.001) and more opioid medication use (29.7% vs. 14.7%, p=0.028). Attempts at surgical procedures or IR embolization were equivalent across groups (p=0.2).